INSP INVESTOR ALERT: Inspire Medical Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead the Inspire Medical Class Action Lawsuit

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to the poor launch of its Inspire V device for obstructive sleep apnea treatment [1][3]. Company Overview - Inspire Medical develops and manufactures an implantable medical device called "Inspire" for treating obstructive sleep apnea, with its latest version being Inspire V, which includes an implanted sensor and neurostimulator [2]. Allegations of the Lawsuit - The lawsuit claims that during the class period, Inspire Medical and its executives made false or misleading statements regarding the launch of Inspire V, asserting that demand was strong when, in fact, there was significant surplus inventory and reluctance from providers to adopt the new treatment [3]. - On August 4, 2025, Inspire Medical disclosed that the launch of Inspire V was facing an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at implanting centers, which hindered the ability to bill for procedures [4]. - Following the negative news, Inspire Medical reduced its 2025 earnings guidance by over 80%, leading to a more than 32% decline in the company's stock price [4]. Legal Process - Investors who purchased Inspire Medical common stock during the class period have until January 5, 2026, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [1][5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone, and is recognized for obtaining significant recoveries in securities class action cases [6].